Neumora pivots to NMRA-511 in AD agitation after navacaprant's three Phase 3 failures; the bet now hinges on whether Phase 1b signals translate to Phase 2 efficacy

Neumora is a clinical-stage biotech company developing a targeted neuropsychiatry drug for agitation in Alzheimer's disease patients, which is not yet approved.

Navacaprant, Neumora's founding kappa opioid receptor antagonist program, failed all three Phase 3 studies in MDD and was discontinued, invalidating the original investment thesis. NMRA-511, a vasopressin V1a receptor antagonist showing Phase 1b effect sizes of 0.51–0.64 (CMAI) in AD agitation, represents the speculative pivot asset — unvalidated at Phase 2 and not yet in registrational study. The AD agitation space already has Rexulti (brexpiprazole, Otsuka/Lundbeck) approved in 2023, setting a high efficacy and safety bar that NMRA-511's early effect sizes have not yet demonstrated the ability to clear.